Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
Sci Rep. 2018 Feb 26;8(1):3642. doi: 10.1038/s41598-018-22034-0.
This randomized, controlled, open-label study conducted in Kangbuk Samsung Hospital evaluated the effectiveness, reproducibility, and durability of tailored mobile coaching (TMC) on diabetes management. The participants included 148 Korean adult policyholders with type 2 diabetes divided into the Intervention-Maintenance (I-M) group (n = 74) and Control-Intervention (C-I) group (n = 74). Intervention was the addition of TMC to typical diabetes care. In the 6-month phase 1, the I-M group received TMC, and the C-I group received their usual diabetes care. During the second 6-month phase 2, the C-I group received TMC, and the I-M group received only regular information messages. After the 6-month phase 1, a significant decrease (0.6%) in HbA1c levels compared with baseline values was observed in only the I-M group (from 8.1 ± 1.4% to 7.5 ± 1.1%, P < 0.001 based on a paired t-test). At the end of phase 2, HbA1c levels in the C-I group decreased by 0.6% compared with the value at 6 months (from 7.9 ± 1.5 to 7.3 ± 1.0, P < 0.001 based on a paired t-test). In the I-M group, no changes were observed. Both groups showed significant improvements in frequency of blood-glucose testing and exercise. In conclusion, addition of TMC to conventional treatment for diabetes improved glycemic control, and this effect was maintained without individualized message feedback.
这项在康伯斯三星医院进行的随机、对照、开放性研究评估了定制移动辅导（TMC）在糖尿病管理中的有效性、可重复性和持久性。参与者包括 148 名韩国成年投保人，他们患有 2 型糖尿病，分为干预维持（I-M）组（n=74）和对照干预（C-I）组（n=74）。干预是在典型的糖尿病护理中加入 TMC。在 6 个月的第 1 阶段，I-M 组接受 TMC，C-I 组接受常规糖尿病护理。在第二个 6 个月的第 2 阶段，C-I 组接受 TMC，而 I-M 组仅接受常规信息消息。在第 1 阶段 6 个月后，仅 I-M 组的 HbA1c 水平与基线值相比显著下降（0.6%）（从 8.1±1.4%降至 7.5±1.1%，基于配对 t 检验，P<0.001）。在第 2 阶段结束时，C-I 组的 HbA1c 水平与 6 个月时相比下降了 0.6%（从 7.9±1.5降至 7.3±1.0，基于配对 t 检验，P<0.001）。在 I-M 组中，没有观察到变化。两组的血糖检测和运动频率均显著改善。总之，将 TMC 添加到常规糖尿病治疗中可以改善血糖控制，而且这种效果在没有个性化信息反馈的情况下得以维持。
